Guildford, UK, and Burlington, Mass., February 22, 2011 – IDBS, a global provider of innovative enterprise data management, analytics and modeling solutions, today announced it will speak at Cambridge Healthtech Institute’s (CHI’s) annual Molecular Medicine Tri-Conference to be held February 23-25 in San Francisco.
The Tri-Conference event brings together leading scientists and executives from multiple therapeutic and diagnostic aspects of the industry to discuss cutting-edge research, trends, and analysis. Dr. Paul Denny-Gouldson, Vice President of Translational Research at IDBS will present a session entitled “Enterprise Translational Medicine: It’s a kind of magic,” as part of the Translational Science track in the conference’s Discovery and Development channel.
The convergence of life science research and medicine is leading to more personalized healthcare. Organizations need to implement advanced clinical research information systems (ACRIS) to combine clinical, molecular and imaging data to support translational research. ACRIS architectures typically have a research data repository (RDR) that is separate from medical record systems and is designed to answer scientific questions and assess patient outcomes. Collaborative web-based access to RDRs enable clinicians and researchers to browse clinical data and easily create patient cohorts. Critically, sample, molecular and research results also stored in the RDR can be used to stratify the patient cohorts.
Dr. Denny-Gouldson’s presentation will detail key lessons learned in designing and developing ACRIS-type systems for oncology, cardiovascular and neuroscience disease areas; it will also look at technical challenges of clinical data ETL and terminology mapping, pseudonymization, coping with large data sets such as Next Gen Sequencing (NGS) and cloud based deployment.
IDBS customer, Daniel Ingber, Senior Manager, Research Information Systems at MedImmune, will also be speaking on “Building a Translational Biomarker Data Mining and Data Warehouse Platform: Considerations”. Mr. Ingber will discuss how to build and manage a system with a flexible data model which supports a scalable, industrial-strength scientific data pipeline, leading to a better understanding of drug action, an improved ability to understand physiological responses, and better overview of inter-relationships between research and clinical data.
The 2011 Molecular Medicine Tri-Conference will be held at the Moscone North Convention Center in San Francisco, February 23-25, 2011. Mr. Ingber and Dr. Denny-Gouldson will present on Wednesday, February 23, at 3:20 and 3:50 pm, respectively. For conference information or to register, visit https://chidb.com/register/2011/mmtc/reg.asp.
IDBS is a global provider of innovative enterprise data management, analytics and modeling solutions. The company’s uniquely sophisticated platform technologies are used by more than 200 pharmaceutical companies, major healthcare providers, global leaders in academic study, and high tech companies to increase efficiency, reduce costs and improve the productivity of industrial R&D and clinical research. IDBS is clearly differentiated by its unique combination of award-winning enterprise technologies and domain knowledge in R&D.
IDBS’ solutions help scientists, hospitals and R&D businesses produce the world’s newest therapeutics, diagnostics and personalized treatments, faster, cleaner engines and fuels, breakthroughs in productive agriculture, healthy, safer food products, and high tech materials and consumer products.
Founded in 1989 and privately held, IDBS is headquartered in Guildford, UK with a direct sales and support presence worldwide. IDBS is a Profit Track 100 company and the recipient of multiple awards including the Frost and Sullivan ‘Enabling Technology’ Award in R&D data management for 2010 and Queen’s Award for International Trade 2011. Further information can be found at www.idbs.com, or follow us on Twitter @IDBSsoftware.